Skip to Content
Merck
CN
  • Endothelial keratoplasty after failed penetrating keratoplasty: an alternative to repeat penetrating keratoplasty.

Endothelial keratoplasty after failed penetrating keratoplasty: an alternative to repeat penetrating keratoplasty.

American journal of ophthalmology (2014-08-26)
Marcus Ang, Henrietta Ho, Cheewai Wong, Hla Myint Htoon, Jodhbir S Mehta, Donald Tan
ABSTRACT

To analyze graft survival of endothelial keratoplasty (EK) under a previous failed penetrating keratoplasty (PK) compared to repeat PK. Retrospective, comparative case series. Analysis involved consecutive patients who underwent either a repeat PK or EK under PK, after failed PK, whose primary surgical indication was pseudophakic bullous keratopathy at a single tertiary center. Clinical data and donor and recipient characteristics were recorded from our prospective cohort from the Singapore Corneal Transplant Study. Main outcome measure was graft survival up to 5 years follow-up. We included a total of 113 eyes that underwent a repeat PK (n = 81) or EK under a failed PK (n = 32). Cumulative graft survival probabilities comparing repeat PK with EK under PK were at 91.9% vs 96.2% (1 year), 82.6% vs 91.6% (2 years), 66.8% vs 86.4% (3 years), and 51.3% vs 86.4% up to 5 years follow-up, respectively (log-rank P value = .013). Multivariate Cox regression analysis was performed, which adjusted for: age, sex, risk factors for graft failure (corneal neovascularization, ocular surface disease, glaucoma, active corneal inflammation, anterior synechiae), donor endothelial cell count, and repeat donor size. Repeat PK was a significant risk factor for graft failure compared to performing an EK under PK (hazard ratio: 10.17; 95% CI 1.10-93.63; P = .041). In our study of eyes with bullous keratopathy, endothelial keratoplasty under a previously failed PK provided better graft survival outcomes than repeat PK, adjusting for potential confounders and risk factors for graft failure.

MATERIALS
Product Number
Brand
Product Description

USP
Cefazolin, United States Pharmacopeia (USP) Reference Standard
Cefazolin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%